We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacteria and CTCs Rapidly Isolated from Difficult Samples

By LabMedica International staff writers
Posted on 07 Dec 2010
New technology enables bacteria or specific target cells to be rapidly isolated from samples such as sputum and blood that contain high levels of debris.

Called the KymaSep system, a combination of magnetic and ultrasound forces (acoustomagnetic) are utilized to control magnetic beads in a flow-through chamber. The coated beads, which are highly specific for the target bacteria or circulating tumor cells (CTCs), can be captured and held on the side of the chamber during aggressive washing and then automatically resuspended and collected.

Intact cells survive the process and can be used for further analysis including microscopy and culture. Unaffected by background cells or debris, acoustomagnetic separation is ideal for a wide range of applications that have proved too challenging for traditional rapid methods, particularly those where target cells or bacteria are present in very low numbers. By processing much larger volumes than other techniques, KymaSep captures sufficient cells to produce highly concentrated samples.

Ongoing applications of the technology include the rapid detection of Mycobacterium tuberculosis (TB) in sputum samples and the capture of CTCs in blood; these applications could have enormous impact in the diagnosis and management of these global killers.

There are 8.9 million new active cases of TB annually with nearly 2 million deaths, making rapid diagnosis a priority for healthcare providers around the world. ProKyma plans to develop a rapid detection test that can be used at the point of care.

CTC analysis is rapidly emerging as an important tool for detecting certain cancers and monitoring response to chemotherapy. Conventional detection is complex and expensive and ProKyma's technology will simplify testing and make it more accessible.

Prokyma Technologies Ltd (Liverpool, UK) won the "Innovation in Diagnostics Project of the Year” award at the Northwest Biomedical Awards on November 12, 2010, for developing the new technology. The award was presented by ThermoFisher (Waltham, MA, USA) to Prokyma, which is a spin out company from the Defence Science and Technology Laboratory (Dstl; Porton Down, UK).

Related Links:
Prokyma Technologies Ltd.
ThermoFisher
Defence Science and Technology Laboratory


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Specimen Radiography System
TrueView 200 Pro
New
Human Estradiol Assay
Human Estradiol CLIA Kit

Latest Technology News

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes
07 Dec 2010  |   Technology

Wireless Sweat Patch Could Be Used as Diagnostic Test for Cystic Fibrosis
07 Dec 2010  |   Technology

New Method Advances AI Reliability with Applications in Medical Diagnostics
07 Dec 2010  |   Technology